In contrast, each SD increase in fasting insulin was associated with an increased risk of pancreatic cancer (OR = 1.66, 95% CI = 1.05 to 2.63) (Figure 1), with little evidence for between-study heterogeneity (Figure 3B). Here, INS is linked to familial pancreatic carcinoma.